On November 5, 2026, a new Phase 3 clinical trial involving cagrilintide, as part of the combination medicine CagriSema, was registered on ClinicalTrials.gov. The trial, titled "A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity," is listed under identifier NCT07919405.
The study is designated Phase 3 and its current status is not yet recruiting. No participants have been enrolled at this stage, and no results have been posted.
Cagrilintide remains an unapproved compound currently under research investigation. This trial update reflects only the registration status and planned design as recorded on the date listed, not any outcome or efficacy finding. No dosing information, safety data, or results are available in this listing.
As the trial has not yet begun recruiting, further details about enrollment timelines, participant criteria, and study locations are expected to be updated as the trial progresses. Readers interested in tracking this study can refer to the official ClinicalTrials.gov registration for updates.
For more background on cagrilintide, including its development history and research status, readers can consult the compound overview.